Filing Flows › Health Care › Prokidney (PROK)
Prokidney (PROK) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 10, 2026 · Prokidney (PROK) Q2 2026 earnings results →
Q2 2026 Revenue down 32% year over year to $150K
Prokidney made $150K in Q2 2026 (-32% Y/Y). Operating margin n/m, net loss $46.4M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 10, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $150K in Q2 2026, down 32% year over year and down 34% from the previous quarter.
Operating costs exceeded revenue by $48.4M, an operating margin of -32248.7%. Total costs grew 22% against a revenue fall of 32%. The fastest-growing cost line was Research & development (+39%). The quarter ended with a net loss of $46.4M, wider than the previous quarter's $42.6M loss. Minority interests bore $18.0M of it: to shareholders the quarter was a loss of $28.4M.
Operating cash flow was −$40.4M. Non-cash charges added back $1.7M of depreciation and amortization and $5.6M of share-based compensation. Capital expenditures of $3.8M exceeded it, leaving free cash flow of −$44.2M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 10, 2026 | $150K | -32% | n/m | −$46.4M | −$40.4M |
| Q1 2026 | 10-Q | May 15, 2026 | $226K | -2% | n/m | −$42.6M | −$41.7M |
| Q4 2025 | 10-K | Mar 18, 2026 | $225K | +196% | n/m | −$40.9M | −$32.5M |
| Q3 2025 | 10-Q | Nov 10, 2025 | $217K | — | n/m | −$35.8M | −$26.6M |
| Q2 2025 | 10-Q | Aug 12, 2025 | $221K | — | n/m | −$37.0M | −$31.4M |
| Q1 2025 | 10-Q | May 12, 2025 | $230K | — | n/m | −$38.0M | −$29.6M |
| Q4 2024 | 10-K | Mar 17, 2025 | $76K | — | n/m | −$48.5M | −$24.2M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Prokidney
ProKidney, a pioneer in the treatment of CKD through innovations in cell therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT ® ), is a first-in-class, patented, proprietary autologous cell therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. For more information, please visit www.prokidney.com .
In its own words, from its 8-K, filed Aug 10, 2026.
Prokidney against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -32% against the peers' median +11%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| PROK Prokidney | Q2 2026 | $150K | -32% | n/m |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
Source: Prokidney 10-Q on SEC EDGAR · CIK 1850270 · Biological Products, (No Diagnostic Substances)
13F: who owns PROK and who is buying
More on PROK
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results